Enveric Biosciences (NASDAQ:ENVB) reported its Q2 2023 financial results, showing a decrease in cash and cash equivalents, increased R&D and G&A expenses, and a net loss attributable to shareholders. The company's management has raised doubts about its ability to continue operations in the next year due to further anticipated losses and no revenue generation. To alleviate these conditions, the company plans to reduce spending, manage cash flow, advance its programs, and raise additional working capital. If unable to raise enough capital, it may cut costs by delaying or discontinuing certain activities at its research facility.